Lori J. Wirth, MD, Massachusetts General Hospital

Articles by Lori J. Wirth, MD, Massachusetts General Hospital

Emerging Targets and Resistance Mechanisms in Advanced Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, highlights future directions in the treatment of radioactive iodine–refractory differentiated thyroid cancer, emphasizing novel targets and mechanisms of resistance.

Managing Adverse Events With Lenvatinib and Pembrolizumab in Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, discusses practical considerations for managing adverse events with the combination of lenvatinib and pembrolizumab in radioactive iodine–refractory differentiated thyroid cancer.

Lenvatinib and Pembrolizumab Combination Therapy in RAI Refractory Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, reviews clinical evidence supporting the combination of lenvatinib and pembrolizumab in radioactive iodine–refractory differentiated thyroid cancer.

Evolving Sequencing Strategies in Advanced Thyroid Cancer Based on Molecular Profile

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, discusses how the expanding treatment landscape in advanced differentiated thyroid cancer has shifted focus toward optimal sequencing of therapies.

Lenvatinib as Preferred First Line Therapy and Sequencing Strategies in RAI Refractory Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, outlines optimal first-line use and sequencing strategies for systemic therapy in radioactive iodine–refractory differentiated thyroid cancer.

Dabrafenib Plus Trametinib in BRAF V600E Mutated Thyroid Cancer After Prior Therapy

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, reviews emerging phase 3 data evaluating dabrafenib plus trametinib in patients with BRAF V600E–mutated advanced differentiated thyroid cancer.

Recommended First Line Targeted Therapy for RET and NTRK Fusion Positive Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, reviews recent National Comprehensive Cancer Network guideline updates for patients with radioactive iodine refractory differentiated thyroid cancer.

Prognostic and Therapeutic Implications of Molecular Genotype in Advanced Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

April 7th 2026

Lori Wirth, MD, explains how molecular profiling in advanced differentiated thyroid cancer informs both treatment selection and prognosis. Identifying actionable genomic alterations enables clinicians to tailor systemic therapy based on tumor genotype, a cornerstone of precision oncology.

Prevalence and Clinical Relevance of BRAF V600E Mutations in Advanced Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital

March 31st 2026

Lori Wirth, MD, discusses the latest NCCN guideline updates in differentiated thyroid cancer.

Precision Oncology in Differentiated Thyroid Cancer and the Role of NGS Testing in First Line Therapy

ByLori J. Wirth, MD, Massachusetts General Hospital

March 31st 2026

Lori Wirth, MD, discusses the latest NCCN guideline updates in differentiated thyroid cancer.

Sequencing Throughout Multiple Lines of Therapy in RR DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

June 5th 2023

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Optimizing Use of RET Inhibitors in Patients With RR DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 29th 2023

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 3: Treating RR DTC With an Identified RET Fusion

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 29th 2023

Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.

Practical Considerations for Utilizing Second-Line Therapy in RR DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 22nd 2023

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

Clinical Data Behind Second-Line Therapy in RR DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 22nd 2023

A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 2: Second-Line Management of RR DTC With Cabozantinib

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 15th 2023

Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.

RR DTC: Managing Adverse Events With Dose Reductions or Holds

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 15th 2023

Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.

Quality of Life and Real-World Data in Patients With RR DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 8th 2023

Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.

Overview of Available Treatment Options for RR DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 8th 2023

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

RR DTC: Active Surveillance vs Initiating Systemic Therapy

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 1st 2023

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

Defining Radioiodine-Refractory Differentiated Thyroid Cancer

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

May 1st 2023

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

Practical Considerations for Managing RR DTC With Systemic Therapy

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

April 24th 2023

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Marcia S. Brose, MD, PhD

April 24th 2023

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Diagnosing DTC: Clinical Workup and Molecular Testing

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Worden, MD,Marcia S. Brose, MD, PhD, University of Pennsylvania

April 17th 2023

Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.

Overview on Differentiated Thyroid Cancer (DTC)

ByLori J. Wirth, MD, Massachusetts General Hospital,Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego,Francis Worden, MD,Marcia Brose, MD, PhD, University of Pennsylvania

April 17th 2023

Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.